ArticleCurrent pathobiology reports2013
Cancer Stem Cells: A Moving Target.
Article in Current pathobiology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure.International journal of molecular sciences · 2019Article
- G-protein-signaling modulator 2 expression and role in a CD133OncoTargets and therapy · 2019Article
- All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis.PloS one · 2017Article
- Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.British journal of clinical pharmacology · 2016Review
- RalA is overactivated in medulloblastoma.Journal of neuro-oncology · 2016Article
- Towards Organs on Demand: Breakthroughs and Challenges in Models of Organogenesis.Current pathobiology reports · 2016Article
- A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids.BioTechniques · 2016Article
- p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.Molecular medicine reports · 2015Article
- Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.Theranostics · 2015Review
- Article
- RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).Molecular oncology · 2014Article
- Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.Molecular cancer research : MCR · 2014Article
- mTOR pathway in colorectal cancer: an update.Oncotarget · 2014Review
- Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Even though the number of anti-cancer drugs entering clinical trials and approved by the FDA has increased in recent years, many cancer patients still experience poor survival outcome. The main explanation for such a dismal prognosis is that current therapies might leave behind a population of cancer cells with the capacity for long-term self-renewal, so-called cancer stem cells (CSCs), from which most tumors are believed to be derived and fueled. CSCs might favor local and distant recurrence even many years after initial treatment, thus representing a potential target for therapies aimed at improving clinical outcome. In this review, we will address the CSC hypothesis with a particular emphasis on its current paradigms and debates, and discuss several mechanisms of CSC resistance to conventional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.